IDH1 and central nervous system cancer: Likewise, Pellegata and colleagues have reported that IDH1 R132H-specific peptide vaccines significantly prolong the survival of mice intracranially implanted with GL-261 glioma cells overexpressing mutant IDH1 but not parental GL-261 [88], suggesting that the immunizations specifically target the IDH1-mutant glioma cells.